Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Effect of long-term corticosteroid treatment on microRNA and gene-expression profiles in Chronic Obstructive Pulmonary Disease

  1. Alen Faiz1,2,3,4,*,
  2. Katrina Steiling5,
  3. Mirjam P. Roffel2,3,
  4. Dirkje S. Postma1,3,
  5. Avrum Spira5,
  6. Marc E. Lenburg5,
  7. Malte Borggrewe2,
  8. Tim R. Eijgenraam2,
  9. Marnix R. Jonker2,
  10. Gerard H. Koppelman3,6,
  11. Simon D. Pouwels1,2,3,
  12. Gang Liu5,
  13. Yuriy O. Alekseyev7,
  14. Stephen Lam8,
  15. Pieter S. Hiemstra9,
  16. Peter J. Sterk10,
  17. Wim Timens2,3,
  18. Corry-Anke Brandsma2,3,
  19. Irene H. Heijink1,2,3,‡ and
  20. Maarten van den Berge1,3,‡
  1. 1University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands
  2. 2University of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, Groningen, The Netherlands
  3. 3University of Groningen, University Medical Center Groningen, GRIAC (Groningen Research Institute for Asthma and COPD), Groningen, The Netherlands
  4. 4University of Technology Sydney, Faculty of Science, Respiratory Bioinformatics and Molecular Biology (RBMB), Ultimo, NSW, Australia
  5. 5Boston University School of Medicine, Division of Computational Biomedicine, Department of Medicine, Boston, Massachusetts, USA
  6. 6University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen, The Netherlands
  7. 7Boston University School of Medicine, Department of Pathology and Laboratory Medicine, Boston, Massachusetts, USA
  8. 8Cancer Imaging, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  9. 9Leiden University Medical Center, Department of Pulmonary Diseases, Leiden, The Netherlands
  10. 10University of Amsterdam, Department of Respiratory Medicine, F5-259, Academic Medical Centre, Amsterdam, The Netherlands
  1. Alen Faiz. E-mail: a.faiz{at}umcg.nl
  1. ‡ Shared last authorship; both authors contributed equally

Abstract

To investigate whether microRNA (miRNA) expression is modulated by inhaled corticosteroid (ICS) treatment, we performed genome-wide miRNA analysis on bronchial biopsies of 69 moderate/severe COPD patients at baseline and after 6- and 30-month treatment with the ICS fluticasone propionate (FP) or placebo. The effect of ICS on miRNA expression was validated in differentiated primary bronchial epithelial cultures, and functional studies were conducted in BEAS-2B cells. MiRNAs affected by ICS and their predicted targets were compared to an independent miRNA dataset of bronchial brushings from COPD patients and healthy controls. Treatment with ICS for both 6- and 30-months significantly altered the expression of 4 miRNAs, including miR-320d, which was increased during ICS treatment compared with placebo. The ICS-induced increase of miR-320d was confirmed in primary airway epithelial cells. MiR-320d negatively correlated targets were enriched for pro-inflammatory genes and were increased in the bronchial brushes of patients with lower lung function in the independent dataset. Overexpression of miR-320d in BEAS-2B cells dampened cigarette smoke extract-induced pro-inflammatory activity via inhibition of nuclear factor (NF)-κB. Collectively, we identified miR-320d as a novel mediator of ICS, regulating the pro-inflammatory response of the airway epithelium.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Alen Faiz

Conflict of interest: Dr. Steiling has a patent “Biomarkers of COPD disease activity” pending.

Conflict of interest: P. Roffel

Conflict of interest: S. Postma

Conflict of interest: Avrum Spira

Conflict of interest: E. Lenburg

Conflict of interest: Malte Borggrewe

Conflict of interest: R. Eijgenraam

Conflict of interest: R. Jonker

Conflict of interest: H. Koppelman

Conflict of interest: D. Pouwels

Conflict of interest: Gang Liu

Conflict of interest: Dr. Alekseyev has nothing to disclose.

Conflict of interest: Stephen Lam

Conflict of interest: S. Hiemstra

Conflict of interest: Dr. Sterk reports grants from GlaxoSmithKline, grants from Dutch Government, during the conduct of the study.

Conflict of interest: Wim Timens

Conflict of interest: Corry-Anke Brandsma

Conflict of interest: H. Heijink

Conflict of interest: Maarten van den Berge

This is a PDF-only article. Please click on the PDF link above to read it.

  • Copyright ©ERS 2019

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society